The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney ...

President Donald Trump announced on Monday that British-Swedish drugmaker AstraZeneca will be investing $50 billion in the ...

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’ s research and manufacturing footprint by the end of 2026. Pascal Soriot ...

Overall Count and Share for 'AstraZeneca United States' based on the 12-month time frame mentioned above.

In the United States, the Biden administration’s moves to order more supply of the three vaccines authorized by the F.D.A. has further sidelined AstraZeneca’s candidate.

British drugmaker AstraZeneca says it has started Phase 3 trials of its coronavirus vaccine candidate in the United States. The vaccine, AZD 1222, is the third to enter large-scale trials in the ...

The table to the right includes counts of all research outputs for AstraZeneca United States published between 1 May 2022 - 30 April 2023 which are tracked by the Nature Index.